VEGZELMA

ਉਤਪਾਦ ਝਲਕ

About VEGZELMA

VEGZELMA is a prescription medication containing the active ingredient Bevacizumab, a recombinant humanized monoclonal antibody. It is used to treat various types of cancer, including colorectal, lung, brain, kidney, and breast cancers.

Key Benefits & Uses

• Treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based chemotherapy
• Treatment of non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel
• Treatment of recurrent glioblastoma
• Treatment of metastatic renal cell carcinoma in combination with interferon alfa
• Treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel

Active Ingredient & Action

Bevacizumab works by inhibiting angiogenesis, the process by which new blood vessels form from pre-existing vessels. It binds to vascular endothelial growth factor (VEGF), a protein that promotes angiogenesis, thereby preventing the formation of new blood vessels that feed tumor growth.

Important Notes

VEGZELMA is administered intravenously and should only be used under the guidance of a qualified healthcare professional. Common side effects include hypertension, proteinuria, and headache. Patients with a history of hemoptysis or gastrointestinal fistulae should be closely monitored. It is essential to follow the recommended dosing schedule and to report any adverse reactions to your healthcare provider.